KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

Allergists and clinical immunologists around the world are increasingly faced with the task of
addressing drug allergy and hypersensitivity due to the increase in drug reactions …

Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis
of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of …

Monoclonal antibodies (mAb) are a major component of cancer therapy. In this review, we
summarize the different therapeutic mAbs that have been successfully developed against …

Introduction: Cancer is a devastating disease; however, several therapeutic advances have
recently been made, wherein EGFR and its family members have emerged as useful …

Extensive crosstalk among ErbB/HER receptors suggests that blocking signaling from more
than one family member may be essential to effectively treat cancer and limit drug …

Cancer therapies targeting epidermal growth factor receptor (EGFR), such as small-
molecule kinase inhibitors and monoclonal antibodies, have been developed as standard …

Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an
attractive therapeutic strategy; however, normal tissue expression represents a significant …

Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …

Targeted therapies have unique toxicity profiles. Common adverse events include rash,
diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity …